Hudson Bay Capital Management’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-364,740
| Closed | -$5.27M | – | 1462 |
|
|
2026
Q1 | $5.27M | Sell |
364,740
-257,760
| -41% | -$3.69M | 0.02% | 489 |
|
|
2025
Q4 | $8.86M | Sell |
622,500
-1,452,500
| -70% | -$14.3M | 0.03% | 368 |
|
|
2025
Q3 | $16.4M | Sell |
2,075,000
-137,690
| -6% | -$980K | 0.05% | 259 |
|
|
2025
Q2 | $12.7M | Sell |
2,212,690
-257,720
| -10% | -$1.66M | 0.04% | 305 |
|
|
2025
Q1 | $20.2M | Buy |
2,470,410
+665,610
| +37% | +$6.16M | 0.06% | 261 |
|
|
2024
Q4 | $17M | Buy |
1,804,800
+379,800
| +27% | +$3.95M | 0.06% | 265 |
|
|
2024
Q3 | $15.2M | Buy |
1,425,000
+357,500
| +33% | +$3.89M | 0.06% | 201 |
|
|
2024
Q2 | $10.6M | Buy |
1,067,500
+265,000
| +33% | +$2.72M | 0.05% | 223 |
|
|
2024
Q1 | $9.45M | Buy |
802,500
+442,500
| +123% | +$5.66M | 0.05% | 180 |
|
|
2023
Q4 | $5.11M | Buy |
360,000
+185,000
| +106% | +$2.1M | 0.03% | 296 |
|
|
2023
Q3 | $2.13M | Buy |
175,000
+20,000
| +13% | +$258K | 0.02% | 468 |
|
|
2023
Q2 | $1.95M | Buy |
155,000
+30,000
| +24% | +$356K | 0.01% | 507 |
|
|
2023
Q1 | $1.39M | Hold |
125,000
| – | – | 0.01% | 566 |
|
|
2022
Q4 | $1.53M | Hold |
125,000
| – | – | 0.02% | 648 |
|
|
2022
Q3 | $1.3M | Sell |
125,000
-55,000
| -31% | -$613K | 0.01% | 816 |
|
|
2022
Q2 | $1.93M | Buy |
180,000
+131,204
| +269% | +$1.08M | 0.01% | 811 |
|
|
2022
Q1 | $462K | Buy |
+48,796
| New | +$458K | 0.01% | 883 |
|
|
2021
Q4 | – | Sell |
-250,000
| Closed | -$2.39M | – | 1127 |
|
|
2021
Q3 | $2.39M | Sell |
250,000
-65,000
| -21% | -$665K | 0.03% | 589 |
|
|
2021
Q2 | $3.04M | Buy |
+315,000
| New | +$3.07M | 0.04% | 501 |
|
|
2020
Q3 | – | Sell |
-39,900
| Closed | -$601K | – | 581 |
|
|
2020
Q2 | $601K | Sell |
39,900
-65,100
| -62% | -$793K | 0.01% | 401 |
|
|
2020
Q1 | $970K | Sell |
105,000
-45,000
| -30% | -$428K | 0.02% | 333 |
|
|
2019
Q4 | $1.46M | Buy |
150,000
+38,400
| +34% | +$352K | 0.03% | 307 |
|
|
2019
Q3 | $895K | Buy |
111,600
+71,600
| +179% | +$777K | 0.02% | 325 |
|
|
2019
Q2 | $499K | Hold |
40,000
| – | – | 0.01% | 351 |
|
|
2019
Q1 | $544K | Sell |
40,000
-110,000
| -73% | -$1.34M | 0.01% | 604 |
|
|
2018
Q4 | $1.44M | Buy |
150,000
+10,000
| +7% | +$110K | 0.02% | 576 |
|
|
2018
Q3 | $1.69M | Buy |
140,000
+40,000
| +40% | +$559K | 0.02% | 495 |
|
|
2018
Q2 | $1.56M | Sell |
100,000
-100,000
| -50% | -$1.51M | 0.02% | 563 |
|
|
2018
Q1 | $3.01M | Buy |
200,000
+100,000
| +100% | +$1.52M | 0.06% | 342 |
|
|
2017
Q4 | $1.44M | Hold |
100,000
| – | – | 0.03% | 364 |
|
|
2017
Q3 | $1.51M | Sell |
100,000
-100,000
| -50% | -$1.32M | 0.04% | 268 |
|
|
2017
Q2 | $2.01M | Sell |
200,000
-100,000
| -33% | -$805K | 0.04% | 335 |
|
|
2017
Q1 | $2.14M | Buy |
+300,000
| New | +$1.9M | 0.03% | 455 |
|
Other funds holding FOLD
Hudson Bay Capital Management's FOLD Position: Q2 2026 in Review
Hudson Bay Capital Management sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 364,740 shares — an estimated $5.27M sold.
Hudson Bay Capital Management first reported a position in FOLD in Q1 2017 and held it in 33 quarters. The position peaked at $20.2M in Q1 2025. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Hudson Bay Capital Management reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Hudson Bay Capital Management sold 364,740 Amicus Therapeutics shares in Q2 2026, an estimated $5.27M.
- Hudson Bay Capital Management first reported a position in Amicus Therapeutics in Q1 2017 and held it in 33 quarters.
- Hudson Bay Capital Management's Amicus Therapeutics position peaked at $20.2M in Q1 2025.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.